24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: High Blood Pressure Common Among Black Young AdultsAHA News: Congenital Heart Disease Linked to Neighborhood Pollution, PovertySome Headway Made Against 'Superbugs,' but Threat Remains: CDCHealth Tip: A Well-Stocked First-Aid KitLung Cancer Report Delivers Good, Bad NewsAHA News: Millions Unaware of Common Heart Attack SymptomsWant Extra Years of Life? Keep Blood Pressure Tightly ControlledTestosterone Supplements Double Men's Odds for Blood Clots: StudyHealth Tip: Treating Post-Nasal DripOpioids Won't Help Arthritis Patients Long-Term: StudyCommon Muscle Relaxant Could Pose Mental Dangers for SeniorsKratom May Cause Liver Damage: StudySupplements Don't Prevent Kidney Disease in Type 2 DiabeticsNew Tool Predicts Odds of Kidney DiseaseVitamin E Acetate Is Leading Suspect in Vaping-Linked Lung Illnesses: CDCVaping-Linked Lung Illnesses Top 2,000, CDC SaysAHA News: Stroke Death Rate Increasing for Middle-Aged AmericansRural Americans Dying More From Preventable Causes Than City DwellersWhy Hand-Washing Beats Hand SanitizersSleepless Nights Could Raise Heart RisksScreening Truckers for Sleep Apnea Cuts Health Insurance CostsDo You Take Biotin Supplements? They Could Affect Your Medical TestsAHA News: Heart Disease Down Over A Generation Among American IndiansRisks Mount for Lonely Hearts After Cardiac SurgeryDaylight Saving Time Bad for Health, Experts ClaimHealth Tip: Prevent BloatingCould a Blood Test for Breast Cancer Become a Reality?One Dead, 8 Hospitalized in Salmonella Outbreak Tied to Ground BeefMost Americans Fear Cancer, but Feel Powerless to Prevent It: SurveyFewer Opioids After Eye Surgery Don't Mean More Post-Op PainDrug Trio Could Give Patients With Cystic Fibrosis a New OptionCould Tissue-Sealing Tape One Day Replace Stitches?Deep Sleep May 'Rinse' Day's Toxins From BrainClose to 1,900 Cases of Vaping-Linked Lung Illness, CDC SaysMeasles Leaves People More Vulnerable to Future InfectionsHealth Tip: Nausea After EatingSooner Is Usually Better for Gallbladder SurgeryProtect Your Heart Through the Holiday SeasonReport Finds Americans' Health Is FlaggingAHA News: Retina Changes Offer Glimpse Into Body's Heart HealthWildfire Smoke Threatens Health for Miles AroundHealth Tip: Hand Swelling During ExerciseToo Many Seniors Back in Hospital for Infections Treated During First StayHealth Tip: Cold, Flu or Allergy?Health Tip: What Your Urine Color May MeanNew Database Shows 'Rare' Diseases Are Not So Rare WorldwideIs Head Injury Causing Dementia? MRI Might ShowAHA News: How Does Hormone Therapy Affect Heart Health in Transgender People?Antihistamines Linked to Delayed Care for Severe Allergic Reaction: StudyCould More Coffee Bring a Healthier Microbiome?
Questions and AnswersLinks
Related Topics

Diabetes

Implant Approved to Improve Symptoms in Advanced Heart Failure


HealthDay News
Updated: Aug 19th 2019

new article illustration

MONDAY, Aug. 19, 2019 (HealthDay News) -- The Barostim Neo System was granted U.S. Food and Drug Administration approval to treat symptoms of patients with advanced heart failure who are not candidates for treatment with other devices such as cardiac resynchronization therapy, the agency announced on Friday.

The device includes a pulse generator implanted below a patient's clavicle and connected to a lead attached to the carotid artery. A physician tests and programs the device after implantation. The Barostim Neo System delivers electrical impulses to baroreceptors to ultimately inhibit production of stress-related hormones and reduce heart failure symptoms. Indications for treatment with the device include regular heart rhythm, not being a candidate for cardiac resynchronization therapy, and left ventricular ejection fraction of ≤35 percent. Contraindications include anatomy that could impair device implantation, certain nervous system disorders, uncontrolled and symptomatic slow heart rate, atherosclerosis, and a known allergy to silicone or titanium.

Approval of the device was based on data from a prospective, multicenter, two-arm, randomized clinical trial of 408 patients with advanced heart failure. All patients received guideline-directed medical therapy and medication, and 125 patients also received the Barostim Neo System implant. Those who received the device improved in six-minute walking tests and reported improvements in quality of life.

Potential complications from the device or implantation include infection, reoperation, low blood pressure, nerve damage, surgical or anesthetic complications, allergic reaction, arterial damage, heart failure exacerbation, stroke, and death. The FDA is requiring the manufacturer to conduct a postapproval study on the device's ability to prolong life and reduce the need for hospitalization.

Approval was granted to CVRx.

More Information